$CRBU News

Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting

HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

Evercore ISI Group Maintains Outperform on Caribou Biosciences, Raises Price Target to $13

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Insights into Caribou Biosciences Q4 Earnings

Caribou Biosciences Q4 EPS $(0.28) Beats $(0.33) Estimate, Sales $3.941M Beat $2.610M Estimate

Caribou Biosciences, Inc. (CRBU) Presents at 2026 Tandem Meetings of ASTCT and CIBMTR - Slideshow

Caribou Biosciences Announces Late-Breaking Presentations Of Vispa-Cel And CB-011 Phase 1 Data At 2026 ASTCT And CIBMTR Tandem Meetings

Caribou Biosciences Announces Late-Breaking Presentations Of Vispa-Cel And CB-011 Phase 1 Data At 2026 ASTCT And CIBMTR Tandem Meetings